Myeloproliferative Disorders × 90 days × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
NCT01758042 2026-03-06

BMT

Massachusetts General Hospital

Phase NA Completed
10 enrolled
NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Dartmouth-Hitchcock Medical Center

Phase 3 Active not recruiting
21 enrolled 19 charts
NCT06131801 2026-02-18

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Children's Hospital Medical Center, Cincinnati

Recruiting
30 enrolled
NCT06001385 2026-02-05

OPTIMIZE

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
313 enrolled
NCT01199562 2026-01-28

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

City of Hope Medical Center

Active not recruiting
153 enrolled